Medicare GLP-1 Bridge: Practical Guide for Agents

GLP-1 medications have become one of the most common and most confusing drug coverage topics in Medicare. Clients hear about Ozempic, Wegovy, Zepbound, Mounjaro, and other GLP-1 medications from doctors, friends, television, and social media. Then they ask a Medicare agent the practical question: “Will Medicare cover it?”

Starting July 1, 2026, that answer becomes more nuanced. CMS is launching the Medicare GLP-1 Bridge, a short-term demonstration that gives certain Medicare Part D beneficiaries access to specified GLP-1 drugs for weight management. CMS says the Bridge runs from July 1, 2026 through December 31, 2027, and operates outside the normal Part D benefit coverage and payment flow.

For agents, the key is not to become a clinical screener or prior authorization specialist. The key is to help clients understand the right pathway: when a GLP-1 should go through the client’s Part D plan, when it may go through the Bridge, what questions to ask the prescriber, and what expectations to set before a client assumes “Medicare covers weight loss shots now.”

If you are preparing for 2027 AEP, this belongs next to the broader CMS 2027 Medicare agent workflow changes and the 2027 Medicare agent certification primer. It is not a Scope of Appointment rule, but it is exactly the kind of Part D scenario that can turn into a complaint when the client hears a simple answer to a complicated coverage question.

The simple version: what is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a temporary CMS demonstration for eligible Medicare Part D beneficiaries who are prescribed certain GLP-1 medications for weight management. CMS states that the Bridge is separate from regular Part D payment and coverage. That means Part D plans do not have to opt in for eligible beneficiaries to access the Bridge, and Part D sponsors do not carry risk for GLP-1 drugs furnished through the Bridge.

The beneficiary cost is also different from normal Part D. CMS says eligible beneficiaries will have a $50 copay, but the drug is furnished outside the Part D benefit. As a result, the Part D deductible does not apply, the $50 does not count toward the beneficiary’s true out-of-pocket costs, and the Low-Income Subsidy does not reduce the Bridge copay.

That last point matters. A client with Extra Help may be used to very low drug copays. Under the Bridge, CMS says LIS does not apply to the $50 Bridge copay. Agents should make sure clients do not confuse the Bridge copay with normal Part D cost sharing.

Why the Bridge exists: Part D still has limits for weight-loss use

Historically, Part D has generally excluded drugs when used for anorexia, weight loss, or weight gain. The statutory language appears in the drug classes that may be excluded or restricted, including agents used for those purposes.

That is why GLP-1 conversations have been so confusing. A medication may be covered by Part D for one FDA-approved medical indication but not for weight loss alone. For example, a GLP-1 prescribed for type 2 diabetes or another Part D-coverable indication may follow the client’s Part D formulary and prior authorization rules. But a GLP-1 prescribed solely for weight management has historically been a different coverage question.

The Bridge does not erase that distinction. Instead, it creates a temporary, separate access pathway for certain GLP-1 weight-management prescriptions that meet CMS’s Bridge criteria.

Which GLP-1 drugs are included?

CMS currently lists Foundayo, Wegovy injection and tablets, and Zepbound KwikPen as eligible GLP-1 drugs under the Bridge when used to reduce excess body weight and maintain weight reduction. CMS also notes that the single-dose vial and single-dose pen formulations of Zepbound are not available through the Bridge and that the product and NDC list may be updated during the demonstration.

This is an important field point for agents: do not use “GLP-1” as if every GLP-1 drug is included. The Bridge is not a blanket approval for every diabetes or weight-management medication in the GLP-1 category. Clients should verify the exact drug, formulation, and indication with the prescriber and pharmacy.

Who may qualify?

CMS states that the Bridge is nationwide and available in all states and territories, but only certain Medicare Part D beneficiaries may qualify. Eligible plan types include stand-alone Prescription Drug Plans and Medicare Advantage coordinated care plans that include drug coverage, such as HMO, HMOPOS, local PPO, and regional PPO MA-PD plans. CMS also states that Part D beneficiaries in SNPs, employer or union group waiver plans, and LI NET are eligible to participate, while certain other plan types are not eligible unless the beneficiary is also enrolled in a stand-alone PDP.

The clinical criteria are handled by the medical provider, not the agent. CMS says a provider must submit a prior authorization request attesting that the beneficiary is prescribed the drug for weight reduction and weight maintenance with ongoing lifestyle modification, and that the beneficiary meets one of the BMI-and-condition pathways at the time GLP-1 therapy is initiated.

In practical terms, the provider must determine whether the beneficiary meets one of these CMS criteria:

• BMI of 35 or higher at the time GLP-1 therapy starts;
• BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension despite treatment with two antihypertensive medications, or chronic kidney disease stage 3a or above;
• BMI of 27 or higher with pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.

Agents should not diagnose, calculate medical eligibility, or tell a client they “qualify.” The safer and more accurate phrasing is: “CMS has published clinical criteria that your prescriber must review and attest to if they believe you may be eligible.”

Who should use Part D instead of the Bridge?

This is one of the most important distinctions in the entire program.

CMS says the Bridge is designed for beneficiaries seeking GLP-1 drugs solely to reduce excess body weight or maintain weight reduction. CMS also states that beneficiaries with type 2 diabetes, obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis indications are eligible to receive GLP-1s through their Part D plan and are therefore ineligible for the Bridge, even if they otherwise meet the Bridge clinical criteria.

For agents, the practical rule is:

That distinction also affects plan reviews. A client taking a GLP-1 for diabetes or another Part D-coverable indication still needs a normal Part D drug review: formulary status, prior authorization, step therapy, pharmacy network, preferred cost-sharing pharmacy, and total drug cost. A client using the Bridge should understand that the Bridge is outside normal Part D cost accumulation.

For the broader deductible, threshold, insulin, vaccine, selected-drug, and payment-plan context, keep the broader 2026 Part D plan review process separate from the Bridge-specific workflow.

For election-period questions around changing Medicare Advantage or Part D coverage outside AEP, keep this separate from the Medicare SEP workflow for agents. The Bridge may affect the drug conversation, but it does not automatically create a plan-change pathway.

How the process works in the real world

CMS says eligible beneficiaries do not have to register or opt in to the Bridge. Access begins through the medical provider, pharmacy, and Bridge central processor.

CMS provider guidance lays out a practical workflow. If the provider believes the patient may be eligible, the provider sends the prescription to the pharmacy and directs the pharmacist to send the claim to the Medicare GLP-1 Bridge for weight management. CMS instructs prescribers to include an obesity diagnosis code from the E66 family and the note “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” on the prescription. If that direction is missing, the pharmacy may send the claim to the Part D plan instead, which may trigger a rejection or Part D prior authorization request.

Once the pharmacy submits the claim to the Bridge, Medicare confirms eligibility. If the beneficiary is eligible and the prescription is for a covered Bridge drug, the pharmacy will receive instructions that prior authorization is required, and the pharmacy typically sends the prior authorization request to the provider within 24 to 72 hours. CMS states that the provider must complete the prior authorization and that approval or denial is communicated within 72 hours of submission.

After the first fill is approved, CMS says subsequent fills generally do not require a new prior authorization unless the patient switches from one covered GLP-1 drug to another. Only 28-day or 30-day fills are covered under the Bridge.

What agents should tell clients

A Medicare agent can be extremely helpful by setting expectations. Here is a compliant, practical way to explain it:

That explanation does three things well. It avoids promising coverage. It separates Part D from the Bridge. And it directs clinical eligibility back to the prescriber.

Common client scenarios agents will see

Agent compliance reminders

GLP-1 conversations are high-risk because clients are motivated, costs are high, and coverage rules are easy to oversimplify. Agents should stay in their lane.

First, avoid saying “Medicare covers weight-loss drugs now.” That is too broad. A better phrase is: “CMS created a temporary Bridge pathway for certain eligible Part D beneficiaries using specific GLP-1 drugs for weight management.”

Second, do not determine clinical eligibility. The provider must submit the prior authorization and attest that the beneficiary meets CMS criteria.

Third, do not steer clients into a plan based on a Bridge claim. The Bridge is not a plan benefit in the normal sense. It operates outside the Part D benefit flow. Plan recommendations should still be based on the client’s complete needs analysis.

Fourth, keep Medicare marketing rules in mind. Medicare.gov explains rules for health plans and agents, including limits around steering, pressure, products outside the agreed appointment scope, and educational events. CMS marketing rules also sit under the Medicare Advantage and Part D marketing framework. If a GLP-1 question turns into plan-specific discussion or enrollment, keep the conversation aligned with the 2027 TPMO disclaimer timing rule, the Scope of Appointment, and the carrier’s approved process.

A practical checklist for Medicare agents

When a client asks about GLP-1 coverage, walk through this checklist:

1. Identify the drug and formulation. Do not rely on the client saying “the shot” or “a GLP-1.” Ask for the exact drug name.
2. Clarify the prescribing purpose. Is it for type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, MASH, or weight management? The indication determines the pathway.
3. Check the client’s Part D situation. The Bridge is for eligible Part D beneficiaries in eligible plan types. If the client has no Part D coverage, the Bridge is not a substitute for enrolling in drug coverage.
4. Separate Bridge cost from Part D cost. The $50 Bridge copay does not follow normal Part D deductible, TrOOP, or LIS rules.
5. Direct medical eligibility to the prescriber. Use CMS criteria as a discussion guide, not as an agent determination.
6. Tell the client what to ask the doctor: “Do I meet the CMS Medicare GLP-1 Bridge criteria?” “Is this being prescribed for weight management or another indication?” “Will your office complete the Bridge prior authorization if the pharmacy requests it?”
7. Tell the client what to ask the pharmacy: “Can you process this through the Medicare GLP-1 Bridge if my prescription is marked for Bridge weight management?” “Do you need my Medicare Beneficiary Identifier?”
8. Document the conversation. Note that you provided general Medicare education, did not determine clinical eligibility, and referred the client to the prescriber and pharmacy for Bridge processing.

What this means during plan reviews

The Medicare GLP-1 Bridge should not replace a normal drug review. It adds another layer.

For clients using GLP-1 drugs for Part D-coverable conditions, agents should still check formulary status, utilization management, pharmacy network, and projected annual cost. For clients who may use the Bridge, agents should still review all other prescriptions because Bridge costs do not flow through normal Part D cost-sharing accumulators.

In other words, the Bridge may help with one specific drug pathway, but it does not make plan selection less important. A client may still have expensive inhalers, insulin, anticoagulants, cancer medications, or brand-name drugs where plan choice makes a major difference.

The practical agent record should show the facts you reviewed, what you explained, and where you directed the clinical questions. If the same conversation also involves plan-specific benefits, enrollment timing, SOA collection, or phone enrollment, keep those records organized with the rest of the client file.

Bottom line for Medicare agents

The Medicare GLP-1 Bridge is a major development, but it is not a simple “Medicare now covers GLP-1s” rule. It is temporary. It applies only to certain drugs and formulations. It is outside normal Part D payment. It has a fixed $50 copay that does not count toward Part D TrOOP and is not reduced by LIS. And the provider, not the agent, must attest to clinical eligibility.

The best agents will use the Bridge as an education opportunity. Explain the difference between Part D and the Bridge. Help clients ask better questions. Avoid coverage promises. Keep the plan review comprehensive. And when in doubt, point back to CMS, the prescriber, and the pharmacy.

This article is for educational purposes only and is not legal, medical, tax, compliance, or insurance advice. Agents should confirm current CMS guidance, carrier rules, state rules, agency policies, approved scripts, and the requirements that apply to their specific sales workflow.

Sources

• Medicare GLP-1 Bridge: Centers for Medicare & Medicaid Services Accessed 2026-06-20.
• Medicare GLP-1 Bridge beneficiary information: Centers for Medicare & Medicaid Services Accessed 2026-06-20.
• Medicare GLP-1 Bridge provider information: Centers for Medicare & Medicaid Services Accessed 2026-06-20.
• Medicare GLP-1 Bridge pharmacy information: Centers for Medicare & Medicaid Services Accessed 2026-06-20.
• Medicare rules for health plans and agents: Medicare.gov Accessed 2026-06-20.
• Social Security Act Section 1927(d)(2): Social Security Administration Accessed 2026-06-20.

Frequently Asked Questions

What is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a temporary CMS demonstration for certain Medicare Part D beneficiaries who are prescribed specified GLP-1 drugs for weight management. It runs outside the normal Part D benefit coverage and payment flow.

When does the Medicare GLP-1 Bridge run?

CMS says the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027.

Does the $50 GLP-1 Bridge copay count toward Part D TrOOP?

No. CMS says the Bridge copay does not count toward true out-of-pocket costs under the Part D plan because the drug is furnished outside the Part D benefit.

Does Extra Help reduce the Medicare GLP-1 Bridge copay?

No. CMS says the Low-Income Subsidy does not reduce the $50 Bridge copay because Bridge drugs are outside the normal Part D payment flow.

Should agents decide whether a client qualifies for the GLP-1 Bridge?

No. Agents should not diagnose, calculate clinical eligibility, or tell a client they qualify. The prescriber must review the CMS criteria and submit the prior authorization attestation if appropriate.

Should a client change Part D plans just to get the GLP-1 Bridge?

Not based on the Bridge alone. CMS says Part D sponsors do not have to opt in because the Bridge operates outside normal Part D payment and coverage. Plan choice still matters for the client's other drugs, pharmacies, benefits, premium, and non-Bridge GLP-1 coverage.